Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01889212|
Recruitment Status : Terminated (Due to technical problems)
First Posted : June 28, 2013
Last Update Posted : October 28, 2016
New treatment strategies have been developed in lung cancer targeting the Epidermal Growth Factor Receptor (EGFR). Patients with an activating mutation in the EGFR have high responds rates to the treatment and should be treated with a EGFR inhibitor as first line of treatment. Some wild type patients do as well respond but selection of these patients is more difficult.
Erlotinib has been labeling with 11C and used as a new PET tracer. Accumulation of the tracer (11C-erlotinib) in tumors has showed promising results for selection of responders.
The investigators now want to conduct a larger clinical study to evaluate if accumulation of tracer on a pre-treatment 11C-erlotinib PET/CT can predict responds to erlotinib.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Other: 11C-erlotinib PET/CT||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||April 2015|
|Experimental: NSCLC, erlotinib treatment, 11C-erlotinib PET/CT||
Other: 11C-erlotinib PET/CT
- Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib [ Time Frame: From date of inclusion until the date of first documented progression on the erlotinib treatment or date of death, whichever came first, assessed up to 30 months ]Accumulation of 11c-erlotinib in tumors will be correlated to PFS on erlotinib treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01889212
|Deparment of oncology, Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Peter Meldgaard, Ph.D MD||Aarhus University Hospital|